|350.95||+1.99||+0.57%||Vol 32.58K||1Y Perf 35.14%|
|Sep 23rd, 2021 13:02 DELAYED|
|- -%||- -|
|Target Price||387.33||Analyst Rating||Moderate Buy 2.19|
|Potential %||10.37||Finscreener Ranking||★★ 46.07|
|Insiders Trans % 3/6/12 mo.||-100/-100/-100||Value Ranking||★★ 47.88|
|Insiders Value % 3/6/12 mo.||-100/-100/-100||Growth Ranking||★★★★★ 69.11|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/-100||Income Ranking||— -|
|Price Range Ratio 52W %||74.80||Earnings Rating||Sell|
|Market Cap||15.93B||Earnings Date||4th Nov 2021|
Today's Price Range
5 Year PE Ratio Range
|10 Years||3 220.27%|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||4th Nov 2021|
|Estimated EPS Next Report||0.98|
|EPS Growth Next 5 Years %||20.00|
|Avg. Weekly Volume||238.30K|
|Avg. Monthly Volume||183.57K|
|Avg. Quarterly Volume||197.08K|
ABIOMED Inc. (NASDAQ: ABMD) stock closed at 348.96 per share at the end of the most recent trading day (a 1.15% change compared to the prior day closing price) with a volume of 174.76K shares and market capitalization of 15.93B. Is a component of S&P 500, Russell 1000 indices and it is traded on NASDAQ exchange. The company belongs in the Medical Devices & Instruments industry, Healthcare sector and employs 1536 people. ABIOMED Inc. CEO is Michael R. Minogue.
The one-year performance of ABIOMED Inc. stock is 35.14%, while year-to-date (YTD) performance is 7.64%. ABMD stock has a five-year performance of 182.49%. Its 52-week range is between 242.73 and 387.4, which gives ABMD stock a 52-week price range ratio of 74.80%
ABIOMED Inc. currently has a PE ratio of 105.30, a price-to-book (PB) ratio of 12.32, a price-to-sale (PS) ratio of 16.86, a price to cashflow ratio of 54.30, a PEG ratio of 2.32, a ROA of 11.12%, a ROC of 12.82% and a ROE of 12.50%. The company’s profit margin is 16.78%, its EBITDA margin is 30.70%, and its revenue ttm is $935.26 Million , which makes it $20.61 revenue per share.
Of the last four earnings reports from ABIOMED Inc., there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.98 for the next earnings report. ABIOMED Inc.’s next earnings report date is 04th Nov 2021.
The consensus rating of Wall Street analysts for ABIOMED Inc. is Moderate Buy (2.19), with a target price of $387.33, which is +10.37% compared to the current price. The earnings rating for ABIOMED Inc. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
ABIOMED Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
ABIOMED Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 14.95, ATR14 : 8.97, CCI20 : -127.61, Chaikin Money Flow : 0.03, MACD : 1.98, Money Flow Index : 27.19, ROC : -6.37, RSI : 47.29, STOCH (14,3) : 18.54, STOCH RSI : 0.34, UO : 50.40, Williams %R : -81.46), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of ABIOMED Inc. in the last 12-months were: Andrew J. Greenfield (Option Excercise at a value of $662 500), Andrew J. Greenfield (Sold 34 312 shares of value $11 104 551 ), David M. Weber (Option Excercise at a value of $300 950), David M. Weber (Sold 13 000 shares of value $4 019 635 ), Dorothy E. Puhy (Sold 5 000 shares of value $1 747 347 ), Martin P. Sutter (Sold 24 900 shares of value $7 501 672 ), Michael R. Minogue (Option Excercise at a value of $1 967 750), Michael R. Minogue (Sold 85 000 shares of value $28 913 282 ), Paul G. Thomas (Sold 663 shares of value $219 301 )
Thu, 05 Aug 2021 02:05 GMT Analysts Offer Insights on Healthcare Companies: Abiomed (ABMD) and SQZ Biotechnologies (SQZ)- TipRanks. All rights reserved.
Copyright © 2016-2021 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 67% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
This could take some time, please wait.